The rapid expansion of GLP-1 receptor agonist prescriptions for metabolic conditions is stressing global pharmaceutical supply chains. Drug manufacturers are diverting substantial capital toward specialized fill-finish manufacturing lines to prevent market deficits.
Supply Chain Bottlenecks
Production constraints center primarily on specialized auto-injector device assembly and cold-storage distribution networks. Major pharmaceutical firms are spending billions to acquire dedicated manufacturing plants to secure internal production output.